Rep. Gilbert Ray Cisneros, Jr. Sells Medpace Holdings, Inc. (NASDAQ:MEDP) Stock

Key Points

• Representative Gilbert Ray Cisneros, Jr. sold shares of Medpace Holdings, Inc. (NASDAQ:MEDP) valued between $1,001 and $15,000 on July 24th, as disclosed on August 14th.
• Medpace recently reported earnings of $3.10 EPS, exceeding analyst expectations of $3.00, with revenue up 14.2% year-over-year.
• Institutional investors now own 77.98% of Medpace's stock, highlighting increased interest from significant financial players.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Medpace Holdings, Inc. NASDAQ: MEDP. In a filing disclosed on August 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medpace stock on July 24th.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of W.R. Berkley NYSE: WRB on 7/31/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 7/31/2025.
• Purchased $1,001 - $15,000 in shares of Dayforce NYSE: DAY on 7/31/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 7/31/2025.
• Sold $1,001 - $15,000 in shares of Avantor NYSE: AVTR on 7/23/2025.
• Purchased $1,001 - $15,000 in shares of Revvity NYSE: RVTY on 7/23/2025.
• Purchased $1,001 - $15,000 in shares of Gulfport Energy NYSE: GPOR on 7/18/2025.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 7/15/2025.
• Purchased $1,001 - $15,000 in shares of PTC NASDAQ: PTC on 7/9/2025.
• Purchased $1,001 - $15,000 in shares of Robinhood Markets NASDAQ: HOOD on 7/9/2025.

Medpace Stock Performance

Shares of MEDP stock traded down $0.77 during mid-day trading on Tuesday, reaching $462.14. 323,418 shares of the company's stock traded hands, compared to its average volume of 728,171. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $501.30. The firm has a 50 day moving average price of $369.30 and a two-hundred day moving average price of $332.71. The firm has a market capitalization of $12.98 billion, a PE ratio of 34.36, a price-to-earnings-growth ratio of 2.91 and a beta of 1.42.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. During the same quarter in the previous year, the firm posted $2.75 EPS. The company's revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Medpace

Hedge funds have recently added to or reduced their stakes in the company. Sone Capital Management LLC bought a new position in Medpace in the 4th quarter worth about $1,318,000. GAMMA Investing LLC boosted its stake in shares of Medpace by 37.1% during the first quarter. GAMMA Investing LLC now owns 307 shares of the company's stock valued at $94,000 after purchasing an additional 83 shares in the last quarter. Fundsmith LLP bought a new position in shares of Medpace during the fourth quarter valued at approximately $42,372,000. Park Avenue Securities LLC boosted its stake in shares of Medpace by 1.8% during the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after purchasing an additional 48 shares in the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of Medpace by 70.7% during the first quarter. UMB Bank n.a. now owns 490 shares of the company's stock valued at $149,000 after purchasing an additional 203 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Activity

In other news, President Jesse J. Geiger sold 41,801 shares of the stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the transaction, the president directly owned 36,503 shares in the company, valued at approximately $16,539,874.33. This trade represents a 53.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the transaction, the general counsel owned 10,343 shares in the company, valued at approximately $4,654,350. This represents a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 112,788 shares of company stock valued at $51,018,354. 20.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. TD Cowen restated a "sell" rating and set a $366.00 target price (up from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Truist Financial upped their target price on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Finally, UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and upped their target price for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Medpace presently has a consensus rating of "Reduce" and an average price target of $406.60.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.